HRMY Stock Analysis: Buy, Sell, or Hold?
HRMY - Harmony Biosciences Holdings, Inc. Common Stock
$33.85
-0.62 (-1.78%)
▼
5d:
+4.49%
30d:
+10.03%
90d:
+21.48%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When HRMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HRMY shows positive signals but monitor for confirmation. Market pricing in 1.9% growth. Moderate conviction.
💡 BUY OPPORTUNITY: HRMY shows positive signals but monitor for confirmation. Market pricing in 1.9% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$63.04
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$39.14
13.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HRMY is currently trading at $33.84, which is considered extended relative to its 30-day fair value range of $30.18 to $32.80. The stock's valuation (Forward PE: 6.2) is in line with its historical norms (5.8). At these levels, the market is pricing in 1.9% annual earnings growth.
Technical Outlook: Technically, HRMY is in a downtrend. Immediate support is located at $30.70, while resistance sits at $35.95.
Market Sentiment: HRMY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $44.36 (+28.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HRMY is in a downtrend. Immediate support is located at $30.70, while resistance sits at $35.95.
Market Sentiment: HRMY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $44.36 (+28.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$30.18 -
$32.80
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.7% below Wall St target ($44.36)
- BULLISH: Expecting earnings turnaround to 1.9% growth with 16.6% revenue growth
Trading Range Analysis
30-Day Trading Range
$30.18 -
$32.80
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$30.70
Resistance Level
$35.95
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.17
Wall Street Target
$44.36
(+28.7%)
Revenue Growth (YoY)
16.6%
Earnings Growth (YoY)
-29.5%
Profit Margin
16.2%
Valuation Premium vs History
+1.9% premium
PE vs Historical
6.2 vs 5.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.9%
(market-implied from PE analysis)
1-Year Target
$35.11
(+2%)
2-Year Target
$35.78
(+4%)
3-Year Target
$36.46
(+6%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
PE COMPRESSION
$34.25
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 27.1%)
$250.92
(+628%)
Base:
(SPY PE: 6.2, Growth: 27.1%)
$70.67
(+105%)
Bear:
(PE: 5.2, Growth: 27.1%)
$60.07
(+74%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 14.19 | Current EPS (TTM): $2.48
Bull Case
$77.44
(+125%)
Analyst growth 100.0%, PE expands to 15.6
Base Case
$70.40
(+104%)
Market implied 100.0%, PE stable at 14.2
Bear Case
$23.94
(-31%)
Severe decline -20.0%, PE contracts to 12.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 15, 2026 10:43 AM ET
Data refreshes hourly during market hours. Next update: 11:43 AM
Data refreshes hourly during market hours. Next update: 11:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRMY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Sandip Kapadia
SELL
3746 shares
2026-01-26
Sandip Kapadia
SELL
20961 shares
2026-01-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$275 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 54 HOLD |
Advanced HRMY Option Strategies
Professional options setups generated by AI based on today's HRMY price and gamma walls.
